Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Multiple Cancer Types

Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Multiple Myeloma

A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 followed by a Randomized Controlled Trial of DFMO with or without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Multiple Cancer Types

Study Evaluating 89ZrPanitumumab for Assessment of Indeterminate Metastatic and/or Primary Lesion(s) on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

Head/Neck

A Phase 2, Open-Label, Study Evaluating Safety and Efficacy of the Loncastuximab in Relapsed/Refractory Marginal Zone Lymphoma

Lymphoma

A Phase 1, Open-Label Dose Escalation and Expansion Study of STX-0712 in Patients with Advanced Hematologic Malignancies

Leukemia

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Neuroblastoma (Pediatrics)

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma